Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06378138 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study title expanded, about 1 wordv5 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 50 to 53v4
  3. Study sites: 30 to 50 Eligibility criteria shortened, about 1 wordv3 Show 1 more changeShow less
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 25, 2024 to May 15, 2024 · Site details revised at 30 of 30 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Apr 25, 2024 to May 15, 2024
    • Site details revised at 30 of 30 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Details
NCT Number NCT06378138
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Hematologic Malignancies
Enrollment 226 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov